Overview

ZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer

Status:
Completed
Trial end date:
2003-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of colorectal cancer. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have locally advanced or metastatic colorectal cancer that has not responded to chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio
Collaborator:
National Cancer Institute (NCI)
Treatments:
Gefitinib